(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 October 2025 (09.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/212519 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 40/11* (2025.01)

(21) International Application Number:
PCT/US2025/022337

(22) International Filing Date:
31 March 2025 (31.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/572,743 01 April 2024 (01.04.2024) US
63/693,844 12 September 2024 (12.09.2024) US

(71) Applicant: **MOONLIGHT BIO, INC.** [US/US]; 1616 Eastlake Ave E., Alexandria LaunchLabs, STE 208, Seattle, Washington 98102 (US).

(72) Inventors: **ALBERSHARDT, Ting-Lan**; 1616 Eastlake Ave. E., Alexandria LaunchLabs STE 208, Seattle, Washington 98102 (US). **INIGUEZ, Amanda Balboni**; 1616 Eastlake Ave. E., Alexandria LaunchLabs STE 208, Seattle, Washington 98102 (US). **JARJOUR, Jordan**; 1616 Eastlake Ave. E., Alexandria LaunchLabs STE 208, Seattle, 98102 (US). **BURNETT, Cassandra Eve**; 1616 Eastlake Ave. E., Alexandria LaunchLabs STE 208, Seattle, 98102 (US). **GARCIA, Julie Marie**; 1616 Eastlake Ave. E., Alexandria LaunchLabs STE 208, Seattle, Washington 98102 (US). **DANIELS, Jay Carroll**; 1616 Eastlake Ave. E., Alexandria LaunchLabs STE 208, Seattle, Washington 98102 (US).

(74) Agent: **DOHERTY, Elizabeth A.** et al.; 245 First Street, 18th Floor, Cambridge, Massachusetts 02142 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: DLL3 BINDING PROTEINS AND USES THEREOF

(57) Abstract: The present disclosure relates to molecules binding to delta-like ligand 3 (DLL3), such as anti-DLL3 chimeric antigen receptors (CARs), anti-DLL3 antibodies including antigen binding domains, bispecific antibodies, antibody conjugates, anti-DLL3 immune cell engagers, and other fusion proteins comprising anti-DLL3 antigen binding domains, and the like, polynucleotides and vectors encoding DLL3 binding molecules, and engineered cells expressing DLL3 binding proteins, and methods of making and using the DLL3 binding proteins.




FIG. 2A

WO 2025/212519 A1

[Continued on next page]

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*